Regulatory and pathogenic mechanisms in human autoimmune myasthenia gravis

Annals of the New York Academy of Sciences

Volumn 1132, Issue , 2008, Pages 135-142

  Le Panse, Rozen ^b   Cizeron Clairac, Géraldine ^b   Cuvelier, Mélinée ^b   Truffault, Frédérique ^b   Bismuth, Jacky ^b   Nancy, Patrice ^b   De Rosbo, Nicole Kerlero ^b   Berrih Aknin, Sonia ^a  

^a UNIVERSITÉ D'ARTOIS   (France)

^b NONE

Author keywords

Anti AChR antibodies; B cells; Chemokines; Germinal center; T cells; Thymic hyperplasia; Thymic remodeling; Treg

Indexed keywords

CORTICOSTEROID; CXCL13 CHEMOKINE; FAS ANTIBODY; INTERFERON; INTERLEUKIN 7 RECEPTOR; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTOME;

ADULT; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CD4+ CD25+ T LYMPHOCYTE; CONFERENCE PAPER; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GERMINAL CENTER; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MALE; MICROARRAY ANALYSIS; MYASTHENIA GRAVIS; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THYMUS HYPERPLASIA; UPREGULATION;

MYOIDA;

EID: 45249100929     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1405.019     Document Type: Conference Paper

References (27)

1. Levine, G.D. & J. Rosai. 1978. Thymic hyperplasia and neoplasia: a review of current concepts. Hum. Pathol. 9 : 495 515.
2. Cohen-Kaminsky, S. et al. 1989. B- and T-cell activation in the thymus of patients with myasthenia gravis. Thymus 14 : 187 193.
3. Leprince, C. et al. 1990. Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis. J. Immunol. 145 : 2115 2122.
4. Cohen-Kaminsky, S. et al. 1989. Evidence of enhanced recombinant interleukin-2 sensitivity in thymic lymphocytes from patients with myasthenia gravis: possible role in autoimmune pathogenesis. J. Neuroimmunol. 24 : 75 85.
5. Feferman, T. et al. 2005. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J. Immunol. 174 : 5324 5331.
6. Emilie, D. et al. 1991. In situ production of interleukins in hyperplastic thymus from myasthenia gravis patients. Hum. Pathol. 22 : 461 468.
7. Moulian, N. et al. 1997. Thymocyte Fas expression is dysregulated in myasthenia gravis patients with anti-acetylcholine receptor antibody. Blood 89 : 3287 3295.
8. Wakkach, A. et al. 1996. Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis. J. Immunol. 157 : 3752 3760.
9. Wakkach, A. et al. 1999. Establishment of a human thymic myoid cell line. Phenotypic and functional characteristics. Am. J. Pathol. 155 : 1229 1240.
10. Melms, A. et al. 1988. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J. Clin. Invest. 81 : 902 908.
11. Le Panse, R. et al. 2006. Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia. J. Immunol. 177 : 7868 7879.
12. Guigou, V. et al. 1991. Individual germinal centres of myasthenia gravis human thymuses contain polyclonal activated B cells that express all the Vh and Vk families. Clin. Exp. Immunol. 83 : 262 266.
13. Fraga, M.F. & M. Esteller. 2007. Epigenetics and aging: the targets and the marks. Trends Genet 23 : 413 418.
14. Irminger-Finger, I. 2007. Science of cancer and aging. J. Clin. Oncol. 25 : 1844 1851.
15. Bertho, J.M. et al. 1997. Phenotypic and immunohistological analyses of the human adult thymus: evidence for an active thymus during adult life. Cell Immunol. 179 : 30 40.
16. Flores, K.G. et al. 1999. Analysis of the human thymic perivascular space during aging. J. Clin. Invest. 104 : 1031 1039.
17. Nancy, P. & S. Berrih-Aknin. 2005. Differential estrogen receptor expression in autoimmune myasthenia gravis. Endocrinology 146 : 2345 2353.
18. Meraouna, A. et al. 2006. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 108 : 432 440.
19. Le Bon, A. et al. 2006. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 176 : 2074 2078.
20. Braun, D., I. Caramalho & J. Demengeot. 2002. IFN-alpha/beta enhances BCR-dependent B cell responses. Int. Immunol. 14 : 411 419.
21. Forster, R. et al. 1999. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99 : 23 33.
22. Legler, D.F. et al. 1998. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J. Exp. Med. 187 : 655 660.
23. Balandina, A. et al. 2005. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105 : 735 741.
24. Liu, W. et al. 2006. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 203 : 1701 1711.
25. Seddiki, N. et al. 2006. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 203 : 1693 1700.
26. Miyawaki, T. et al. 1992. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol. 149 : 3753 3758.
27. Iwasa, K. 1997. Striational autoantibodies in myasthenia gravis mainly react with ryanodine receptor. Muscle Nerve 20 : 753 756.